Distinguished in Squamous Cell Lung Carcinoma

Dr. Michael K. Farris

Radiation Oncology
Wake Forest University Health Sciences
Parkwood Dr, 
Elkin, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Squamous Cell Lung Carcinoma
Wake Forest University Health Sciences
Parkwood Dr, 
Elkin, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Farris is a Radiation Oncologist in Elkin, North Carolina. Dr. Farris is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Splenectomy, and Gamma Knife Radiosurgery. Dr. Farris is currently accepting new patients.

His clinical research consists of co-authoring 59 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Squamous Cell Lung Carcinoma.

Specialties
Radiation Oncology
Licenses
Radiology in NC
Hospital Affiliations
North Carolina Baptist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

WAKE FOREST UNIVERSITY HEALTH SCIENCES
Parkwood Dr, Elkin, NC 28621

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Randomized Trial of Consolidative Immunotherapy With vs Without Thoracic Radiotherapy and / or Stereotactic Body Radiation Therapy (SBRT) After First-Line Systemic Therapy for Metastatic NSCLC
A Randomized Trial of Consolidative Immunotherapy With vs Without Thoracic Radiotherapy and / or Stereotactic Body Radiation Therapy (SBRT) After First-Line Systemic Therapy for Metastatic NSCLC
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study of Local Consolidative Radiotherapy Versus Standard of Care Second Line Systemic Therapy in Patients With Oligoprogressive NSCLC on Immune Checkpoint Inhibitors
A Randomized Phase II Study of Local Consolidative Radiotherapy Versus Standard of Care Second Line Systemic Therapy in Patients With Oligoprogressive NSCLC on Immune Checkpoint Inhibitors
Enrollment Status: Withdrawn
Publish Date: April 17, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Single Arm Phase II Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients Who Decline or Are Ineligible for Surgery or Chemotherapy
A Single Arm Phase II Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients Who Decline or Are Ineligible for Surgery or Chemotherapy
Enrollment Status: Terminated
Publish Date: October 05, 2022
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

59 Total Publications

Preclinical Study of Pain Neuropeptide Expression in Murine Sensory Neurons Induced by Irradiated Osteoclasts in the Context of Stereotactic Body Radiation Therapy.
Preclinical Study of Pain Neuropeptide Expression in Murine Sensory Neurons Induced by Irradiated Osteoclasts in the Context of Stereotactic Body Radiation Therapy.
Journal: Cells
Published: June 03, 2025
Similar Doctors
Distinguished in Squamous Cell Lung Carcinoma
Dr. James D. Kinard
Radiation Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. James D. Kinard
Radiation Oncology

Greensboro Radiation Oncologists PA

501 N Elam Ave, 
Greensboro, NC 
 (57.8 miles away)
336-832-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Kinard is a Radiation Oncologist in Greensboro, North Carolina. Dr. Kinard is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Kinard is currently accepting new patients.

Advanced in Squamous Cell Lung Carcinoma
Dr. John S. Moody
Radiation Oncology
Advanced in Squamous Cell Lung Carcinoma
Dr. John S. Moody
Radiation Oncology

Greensboro Radiation Oncologists PA

501 N Elam Ave, 
Greensboro, NC 
 (57.8 miles away)
336-832-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Moody is a Radiation Oncologist in Greensboro, North Carolina. Dr. Moody is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Breast Cancer, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor. Dr. Moody is currently accepting new patients.

Advanced in Squamous Cell Lung Carcinoma
Dr. Sarah E. Squire
Radiation Oncology
Advanced in Squamous Cell Lung Carcinoma
Dr. Sarah E. Squire
Radiation Oncology

Greensboro Radiation Oncologists PA

501 N Elam Ave, 
Greensboro, NC 
 (57.8 miles away)
336-832-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Squire is a Radiation Oncologist in Greensboro, North Carolina. Dr. Squire is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Laryngeal Cancer, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Breast Cancer. Dr. Squire is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farris's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile